Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | CEL | P19835 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786309 | 0.98 | ENPP2 (0.40) | ENPP2KDM4EALDH1A1EPHX1NUDT1 | |
| SCHEMBL3791170 | 0.96 | ENPP2 (0.41) | ENPP2KDM4EALDH1A1EPHX1HIF1A | |
| SCHEMBL3784565 | 0.93 | ENPP2 (0.44) | ENPP2KDM4EALDH1A1F11CA1 | |
| SCHEMBL3786297 | 0.86 | ENPP2 (0.37) | ENPP2KDM4EALDH1A1EPHX1NUDT1 | |
| SCHEMBL3788528 | 0.84 | BACE1 (0.36) | ENPP2KDM4EALDH1A1EPHX1NUDT1 | |
| SCHEMBL3781061 | 0.83 | ENPP2 (0.38) | ENPP2KDM4EALDH1A1EPHX1NUDT1 | |
| SCHEMBL3790596 | 0.82 | ENPP2 (0.37) | ENPP2KDM4EALDH1A1NUDT1BACE1 | |
| SCHEMBL3783481 | 0.81 | HIF1A (0.38) | ENPP2KDM4EALDH1A1EPHX1NUDT1 | |
| SCHEMBL5047801 | 0.79 | ENPP2 (0.38) | ENPP2KDM4EALDH1A1HIF1ACA1 | |
| SCHEMBL3790241 | 0.78 | ENPP2 (0.39) | ENPP2KDM4EALDH1A1F11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ENPP2 1920/4885KDM4E 2606/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.